KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Other Non-Current Assets (2016 - 2025)

Vertex Pharmaceuticals (VRTX) has 17 years of Other Non-Current Assets data on record, last reported at $1.0 billion in Q1 2025.

  • For Q1 2025, Other Non-Current Assets rose 8735.96% year-over-year to $1.0 billion; the TTM value through Mar 2025 reached $1.0 billion, up 8735.96%, while the annual FY2024 figure was $999.3 million, 31128.12% up from the prior year.
  • Other Non-Current Assets reached $1.0 billion in Q1 2025 per VRTX's latest filing, up from $999.3 million in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $1.0 billion in Q1 2025 and bottomed at $3.2 million in Q4 2023.
  • Average Other Non-Current Assets over 5 years is $344.2 million, with a median of $127.3 million recorded in 2022.
  • The widest YoY moves for Other Non-Current Assets: up 31128.12% in 2024, down 97.33% in 2024.
  • A 5-year view of Other Non-Current Assets shows it stood at $5.1 million in 2021, then surged by 56.86% to $8.0 million in 2022, then crashed by 60.0% to $3.2 million in 2023, then surged by 31128.12% to $999.3 million in 2024, then rose by 0.8% to $1.0 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Other Non-Current Assets were $1.0 billion in Q1 2025, $999.3 million in Q4 2024, and $990.2 million in Q3 2024.